University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Mitchel S. Berger, MD

Mitchel S. Berger, MD

Chair, Department of Neurological Surgery, and Director, Brain Tumor Research Center, UCSF
Berthold and Belle N. Guggenhime Professorship, UCSF

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

Dr. Berger's main clinical interests are the treatment of brain tumors in adults and children and of epilepsy related to brain tumors. He has extensive expertise in intraoperative mapping of the brain to identify the sites of motor, sensory, and language function and thereby avoid their involvement or injury during surgery.

Dr. Berger is Director of the Neuro-Oncology Surgery Program. His current research interests involve identifying molecular markers in gliomas as correlates of tumor progression and prognosis. He also works in conjunction with Dr. Krys Bankiewicz to test small molecule inhibitors in brain tumors using convection enhanced delivery. Other collaborations include functional mapping localization of language pathways in the brain in conjunction with Dr. Robert Knight and the Cognitive Neuroscience Graduate Program at UC Berkeley. Dr. Berger is currently the Principal Investigator of UCSF's SPORE Brain Tumor Program. He is also the Principal Investigator of a Pediatric Brain Tumor Foundation Institute award to study the origins and treatment of pediatric brain tumors.

Education

Harvard University, Cambridge, MA, A.B., 1975, Social Psychology
University of Miami, Miami, FL, M.D., 1979, Medicine
University of California, San Francisco, CA (UCSF), Dept. of Neurological Surgery, Brain Tumor Research Center (BTRC) Research Fellow 1983 - 1984 Neurosurgery
UCSF, BTRC, Neuro-Oncology Service, Clinical Fellow, 7/85 - 12/85, Neurosurgery
Hospital for Sick Children, Toronto, Ontario, Canada, Pediatric Neurosurgery Fellow, 1/86 - 6/86, Neurosurgery


Professional Experience

  • 1980 - 1982
    Residency, Dept. of Neurological Surgery, University of California, San Francisco, CA (UCSF)
  • 1986 - 1992
    Asst. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1990 - 1992
    Assoc. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1995 - 1992
    American Cancer Society Prof. of Clinical Oncology, University of Washington, Seattle, WA
  • 1996 - 1992
    Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1997 - present
    Professor and Chair, Dept. of Neurological Surgery, UCSF, San Francisco, CA
  • 1997 - present
    Director, Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF

Honors & Awards

  • 1997-Present
    Joint Section on Tumors Advisory Council, American Association of Neurological Surgeons and Congress of Neurological Surgeons
  • 1997-1999
    Vice-President, Congress of Neurological Surgeons; President, Society for Neuro-Oncology
  • 2002-Present
    America’s Top Doctors, peer-nominated referral index from Castle Connolly
  • 2006
    Tumor Section, 2006 Ronald L. Bittner Lecturer; 2006 Farber Award Winner
  • 2007–Present
    Board of Directors of the American Association of Neurological Surgeons
  • 2007–Present
    Member of the American Board of Neurological Surgeons
  • 2010
    Vice-President, American Association of Neurological Surgeons
  • 2011
    President Elect, American Association of Neurological Surgeons
  • 2012
    President, American Association of Neurological Surgeons

Selected Publications

  1. Oberheim Bush NA, Hervey-Jumper SL, Berger MS. Management of Glioblastoma, Present and Future. World Neurosurg. 2019 Nov; 131:328-338.
    View on PubMed
  2. Wadhwa H, Shah SS, Shan J, Cheng J, Beniwal AS, Chen JS, Gill SA, Mummaneni N, McDermott MW, Berger MS, Aghi MK. The neurosurgery applicant's "arms race": analysis of medical student publication in the Neurosurgery Residency Match. J Neurosurg. 2019 Nov 01; 1-9.
    View on PubMed
  3. Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, Fung KM, Sung S, Glenn C, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Alva E, Johnston J, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA. Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathol. 2019 Oct 14.
    View on PubMed
  4. Sankaran S, Andrews JP, Chicas M, Wachter RM, Berger MS. Patient safety movement in neurological surgery: the current state and future directions. J Neurosurg. 2019 Oct 04; 1-11.
    View on PubMed
  5. Young JS, Morshed RA, Mansoori Z, Cha S, Berger MS. Disruption of the Frontal Aslant Tract is Not Associated with Long-Term Postoperative Language Deficits: A Case Report. World Neurosurg. 2019 Sep 28.
    View on PubMed
  6. Zhu P, Du XL, Blanco AI, Ballester LY, Tandon N, Berger MS, Zhu JJ, Esquenazi Y. Impact of facility type and volume in low-grade glioma outcomes. J Neurosurg. 2019 Sep 27; 1-11.
    View on PubMed
  7. Samuel N, Berger M. Cultural evolution: a Darwinian perspective on patient safety in neurosurgery. J Neurosurg. 2019 Sep 13; 1-7.
    View on PubMed
  8. Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke JL, Torkildson J, Kline C, Reddy A, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni PV, Chou D, Tan L, Theodosopoulos P, McDermott M, Berger M, Raffel C, Gupta N, Sun PP, Li Y, Shah V, Cha S, Braunstein S, Raleigh DR, Samuel D, Scharnhorst D, Fata C, Guo H, Moes G, Kim JYH, Koschmann C, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Phillips JJ, Tihan T, Bollen AW, Perry A, Solomon DA. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathol. 2019 Sep 12.
    View on PubMed
  9. Rubio RR, Chae R, Khare A, Dubnicoff T, Winkler E, Sloan E, Bollen AW, Berger MS, Abla AA. Supracerebellar Approach to Radiation-Induced Giant Capillary Telangiectasia Within Juvenile Pilocytic Astrocytoma of Upper Brainstem. World Neurosurg. 2019 Aug 31; 132:57.
    View on PubMed
  10. Jahangiri A, Flanigan PM, Arnush M, Chandra A, Rick JW, Choi S, Chou A, Berger MS, Aghi MK. From bench to bedside: trends in National Institutes of Health funding for neurosurgeons from 1991 to 2015. J Neurosurg. 2019 Aug 30; 1-10.
    View on PubMed
  11. Sabelström H, Petri R, Shchors K, Jandial R, Schmidt C, Sacheva R, Masic S, Yuan E, Fenster T, Martinez M, Saxena S, Nicolaides TP, Ilkhanizadeh S, Berger MS, Snyder EY, Weiss WA, Jakobsson J, Persson AI. Driving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma Aggressiveness. Cell Rep. 2019 Aug 20; 28(8):2064-2079.e11.
    View on PubMed
  12. Hendriks EJ, Idema S, Hervey-Jumper SL, Bernat AL, Zwinderman AH, Barkhof F, Vandertop WP, Mandonnet E, Duffau H, Berger MS, De Witt Hamer PC. Preoperative Resectability Estimates of Nonenhancing Glioma by Neurosurgeons and a Resection Probability Map. Neurosurgery. 2019 Aug 01; 85(2):E304-E313.
    View on PubMed
  13. McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. Mol Cancer Ther. 2019 Sep; 18(9):1565-1576.
    View on PubMed
  14. Chandra A, Young JS, Dalle Ore C, Dayani F, Lau D, Wadhwa H, Rick JW, Nguyen AT, McDermott MW, Berger MS, Aghi MK. Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma. J Neurosurg. 2019 Jun 21; 1-11.
    View on PubMed
  15. Gittleman H, Cioffi G, Chunduru P, Molinaro AM, Berger MS, Sloan AE, Barnholtz-Sloan JS. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. Neurooncol Adv. 2019 May-Dec; 1(1):vdz007.
    View on PubMed
  16. Widhalm G, Olson J, Weller J, Bravo J, Han SJ, Phillips J, Hervey-Jumper SL, Chang SM, Roberts DW, Berger MS. The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas. J Neurosurg. 2019 May 10; 1-10.
    View on PubMed
  17. Morshed RA, Young JS, Hervey-Jumper SL, Berger MS. The management of low-grade gliomas in adults. J Neurosurg Sci. 2019 Aug; 63(4):450-457.
    View on PubMed
  18. Lee JC, Mazor T, Lao R, Wan E, Diallo AB, Hill NS, Thangaraj N, Wendelsdorf K, Samuel D, Kline CN, Banerjee A, Auguste K, Raffel C, Gupta N, Berger M, Raleigh DR, Shai A, Phillips JJ, Bollen AW, Tihan T, Perry A, Costello J, Solomon DA. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. Acta Neuropathol. 2019 May; 137(5):851-854.
    View on PubMed
  19. Morshed RA, Young JS, Safaee M, Sankaran S, Berger MS, McDermott MW, Hervey-Jumper SL. Delirium Risk Factors and Associated Outcomes in a Neurosurgical Cohort: A Case-Control Study. World Neurosurg. 2019 Jun; 126:e930-e936.
    View on PubMed
  20. Sabelström H, Quigley DA, Fenster T, Foster DJ, Fuchshuber CAM, Saxena S, Yuan E, Li N, Paterno F, Phillips JJ, James CD, Norling B, Berger MS, Persson AI. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells. Exp Cell Res. 2019 May 01; 378(1):76-86.
    View on PubMed

Go to UCSF Profiles, powered by CTSI